Daniel J Diekema

List of Publications by Year
in descending order

264 papers	29,768 citations	3726 89 h-index	5384 164 g-index
265 all docs	265 docs citations	265 times ranked	19166 citing authors

#	Article	IF	Citations
1	Insertion site inflammation was associated with central-lineâ€“associated bloodstream infections at a tertiary-care center, 2015â€“2018. Infection Control and Hospital Epidemiology, 2021, 42, 348-350.	1.0	3
2	Successful termination of an outbreak of Mycobacterium chimaera infections associated with contaminated heater-cooler devices. Infection Control and Hospital Epidemiology, 2021, 42, 471-473.	1.0	4
3	Contamination of health-care workers' hands with Escherichia coli and Klebsiella species after routine patient care: a prospective observational study. Clinical Microbiology and Infection, 2020, 26, 760-766.	2.8	3
4	Incidence and Outcomes Associated WithClostridium difficileInfections. JAMA Network Open, 2020, 3, e1917597.	2.8	78
5	Long-term follow-up of post-cardiac surgery Mycobacterium chimaera infections: A 5-center case series. Journal of Infection, 2020, 80, 197-203.	1.7	6
6	Reduction in abdominal hysterectomy surgical site infection rates after the addition of anaerobic antimicrobial prophylaxis. Infection Control and Hospital Epidemiology, 2020, 41, 1469-1471.	1.0	0
7	Negative pressure face shield for flexible laryngoscopy in the <scp>COVID</scp>â€19 era. Laryngoscope Investigative Otolaryngology, 2020, 5, 718-726.	0.6	12
8	Administrative coding methods impact surgical site infection rates. Infection Control and Hospital Epidemiology, 2020, 41, 1461-1463.	1.0	0
9	A primer on data visualization in infection prevention and antimicrobial stewardship. Infection Control and Hospital Epidemiology, 2020, 41, 948-957.	1.0	8
10	A randomized control trial evaluating efficacy of antimicrobial impregnated hospital privacy curtains in an intensive care setting. American Journal of Infection Control, 2020, 48, 862-868.	1.1	9
11	Impact of Infectious Disease Consultation in Patients With Candidemia: A Retrospective Study, Systematic Literature Review, and Meta-analysis. Open Forum Infectious Diseases, 2020, 7, ofaa270.	0.4	26
12	Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012â€“2017). Diagnostic Microbiology and Infectious Disease, 2020, 97, 115016.	0.8	26
13	Moving Personal Protective Equipment Into the Community. JAMA - Journal of the American Medical Association, 2020, 323, 2252.	3.8	112
14	Genomic Analysis of Cardiac Surgeryâ€“Associated Mycobacterium chimaera Infections, United States. Emerging Infectious Diseases, 2019, 25, 559-563.	2.0	25
15	Impact of expanded influenza post-exposure prophylaxis on healthcare worker absenteeism at a tertiary care center during the 2017â€“2018 season. Infection Control and Hospital Epidemiology, 2019, 40, 260-261.	1.0	1
16	Comparing brief, covert, directly observed hand hygiene compliance monitoring to standard methods: A multicenter cohort study. American Journal of Infection Control, 2019, 47, 346-348.	1.1	11
17	Research Agenda for Microbiome Based Research for Multidrug-resistant Organism Prevention in the Veterans Health Administration System. Infection Control and Hospital Epidemiology, 2018, 39, 202-209.	1.0	2
18	Impact of 2018 Changes in National Healthcare Safety Network Surveillance for Clostridium difficile Laboratory-Identified Event Reporting. Infection Control and Hospital Epidemiology, 2018, 39, 886-888.	1.0	7

#	Article	IF	Citations
19	Discontinuing contact precautions for multidrug-resistant organisms: A systematic literature review and meta-analysis. American Journal of Infection Control, 2018, 46, 333-340.	1.1	61
20	Infection prevention strategies for procedures performed outside operating rooms: A conceptual integrated model. American Journal of Infection Control, 2018, 46, 94-96.	1.1	2
21	Failure of Risk-Adjustment by Test Method for C. difficile Laboratory-Identified Event Reporting. Infection Control and Hospital Epidemiology, 2017, 38, 109-111.	1.0	28
22	Rising Stakes for Health Care-Associated Infection Prevention: Implications for the Clinical Microbiology Laboratory. Journal of Clinical Microbiology, 2017, 55, 996-1001.	1.8	17
23	Mycobacterium chimaera Infections Associated With Contaminated Heater-Cooler Devices for Cardiac Surgery: Outbreak Management. Clinical Infectious Diseases, 2017, 65, 669-674.	2.9	42
24	Mycobacterium chimaera Outbreak Associated With Heater-Cooler Devices: Piecing the Puzzle Together. Infection Control and Hospital Epidemiology, 2017, 38, 103-108.	1.0	65
25	Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014. JAMA Internal Medicine, 2017, 177, 1489.	2.6	84
26	Diagnostic Stewardshipâ€"Leveraging the Laboratory to Improve Antimicrobial Use. JAMA - Journal of the American Medical Association, 2017, 318, 607.	3.8	176
27	Incidence of Extended-Spectrum Î²-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review. Infection Control and Hospital Epidemiology, 2017, 38, 1209-1215.	1.0	124
28	Investigation of a Candida guilliermondii Pseudo-outbreak Reveals a Novel Source of Laboratory Contamination. Journal of Clinical Microbiology, 2017, 55, 1080-1089.	1.8	1
29	Increased Mortality Rates Associated withStaphylococcus aureusand Influenza Co-infection, Maryland and Iowa, USA1. Emerging Infectious Diseases, 2016, 22, 1253-1256.	2.0	29
30	Detection and Prevalence of Penicillin-Susceptible Staphylococcus aureus in the United States in 2013. Journal of Clinical Microbiology, 2016, 54, 812-814.	1.8	29
31	Multilaboratory Evaluation of In Vitro Antifungal Susceptibility Testing of Dermatophytes for ME1111. Journal of Clinical Microbiology, 2016, 54, 662-665.	1.8	7
32	Lessons Learned From Hospital Ebola Preparation. Infection Control and Hospital Epidemiology, 2015, 36, 627-631.	1.0	30
33	Association of a Bundled Intervention With Surgical Site Infections Among Patients Undergoing Cardiac, Hip, or Knee Surgery. JAMA - Journal of the American Medical Association, 2015, 313, 2162.	3.8	245
34	Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint. Antimicrobial Agents and Chemotherapy, 2015, 59, 1759-1766.	1.4	7
35	Comparative Effectiveness of Beta-Lactams Versus Vancomycin for Treatment of Methicillin-SusceptibleStaphylococcus aureusBloodstream Infections Among 122 Hospitals. Clinical Infectious Diseases, 2015, 61, 361-367.	2.9	170
36	Phaeoacremonium parasiticum phaeohyphomycosis in a patient with systemic lupus erythematosus treated successfully with surgical debridement and voriconazole: A case report and review of the literature. IDCases, 2014, 1, 84-88.	0.4	3

#	Article	IF	Citations
37	Ebola Fever: Reconciling Planning With Risk in U.S. Hospitals. Annals of Internal Medicine, 2014, 161, 751.	2.0	20
38	Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 577-580.	1.4	67
39	Reconsidering Isolation Precautions for Endemic Methicillin-ResistantStaphylococcus aureusand Vancomycin-ResistantEnterococcus. JAMA - Journal of the American Medical Association, 2014, 312, 1395.	3.8	42
40	Ebola Virus Disease and the Need for New Personal Protective Equipment. JAMA - Journal of the American Medical Association, 2014, 312, 2495.	3.8	39
41	Activities of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus Isolates Collected in a 2011 National Surveillance Study in the United States. Antimicrobial Agents and Chemotherapy, 2014, 58, 740-745.	1.4	32
42	Multicenter Study of Anidulafungin and Micafungin MIC Distributions and Epidemiological Cutoff Values for Eight Candida Species and the CLSI M27-A3 Broth Microdilution Method. Antimicrobial Agents and Chemotherapy, 2014, 58, 916-922.	1.4	42
43	Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 1748-1754.	1.3	234
44	Concordance of nasal and diabetic foot ulcer staphylococcal colonization. Diagnostic Microbiology and Infectious Disease, 2014, 79, 85-89.	0.8	18
45	Continued Emergence of USA300 Methicillin-ResistantStaphylococcus aureusin the United States: Results from a Nationwide Surveillance Study. Infection Control and Hospital Epidemiology, 2014, 35, 285-292.	1.0	150
46	Multicenter Evaluation of the New Vitek 2 Yeast Susceptibility Test Using New CLSI Clinical Breakpoints for Fluconazole. Journal of Clinical Microbiology, 2014, 52, 2126-2130.	1.8	21
47	Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria. Journal of Clinical Microbiology, 2014, 52, 108-114.	1.8	59
48	Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States. Antimicrobial Agents and Chemotherapy, 2014, 58, 6484-6489.	1.4	136
49	Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of Candida by Using CLSI Methods and Interpretive Criteria. Journal of Clinical Microbiology, 2014, 52, 3223-3229.	1.8	44
50	Methicillin-resistant Staphylococcus aureus prevention practices in hospitals throughout a rural state. American Journal of Infection Control, 2014, 42, 868-873.	1.1	3
51	Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagnostic Microbiology and Infectious Disease, 2014, 79, 205-208.	0.8	43
52	Antibacterial properties of the CFTR potentiator ivacaftor. Journal of Cystic Fibrosis, 2014, 13, 515-519.	0.3	83
53	Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004â€“2008. PLoS ONE, 2014, 9, e101510.	1.1	338
54	Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease, 2013, 77, 37-40.	0.8	30

#	Article	IF	Citations
55	Rapid Detection of Antibiotic-Resistant Organism Carriage for Infection Prevention. Clinical Infectious Diseases, 2013, 56, 1614-1620.	2.9	60
56	Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999â€“20111. Emerging Infectious Diseases, 2013, 19, 1074-1083.	2.0	178
57	Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2013, 57, 5642-5648.	1.4	52
58	Chlorhexidine and Mupirocin Susceptibilities of Methicillin-Resistant Staphylococcus aureus from Colonized Nursing Home Residents. Antimicrobial Agents and Chemotherapy, 2013, 57, 552-558.	1.4	76
59	Developing a New, National Approach to Surveillance for Ventilator-Associated Events. American Journal of Critical Care, 2013, 22, 469-473.	0.8	38
60	Evaluation of Pneumococcal Serotyping by Multiplex PCR and Quellung Reactions. Journal of Clinical Microbiology, 2013, 51, 4193-4195.	1.8	22
61	Long-Term Risk for Readmission, Methicillin-Resistant Staphylococcus aureus (MRSA) Infection, and Death among MRSA-Colonized Veterans. Antimicrobial Agents and Chemotherapy, 2013, 57, 1169-1172.	1.4	22
62	Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary. Clinical Infectious Diseases, 2013, 57, 1742-1746.	2.9	55
63	Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs. Journal of Clinical Microbiology, 2013, 51, 117-124.	1.8	88
64	Contributions of Aspergillus fumigatus ATP-Binding Cassette Transporter Proteins to Drug Resistance and Virulence. Eukaryotic Cell, 2013, 12, 1619-1628.	3.4	78
65	Public Reporting of Health Careâ€“Associated Surveillance Data: Recommendations From the Healthcare Infection Control Practices Advisory Committee. Annals of Internal Medicine, 2013, 159, 631.	2.0	53
66	Antimicrobial Therapy for Bloodstream Infection Due to Methicillin-Susceptible Staphylococcus aureus in an Era of Increasing Methicillin Resistance: Opportunities for Antimicrobial Stewardship. Annals of Pharmacotherapy, 2012, 46, 904-905.	0.9	5
67	In Vitro Activity of Ceftaroline against Clinical Isolates of Streptococcus pneumoniae Recovered in 43 U.S. Medical Centers during 2010-2011. Antimicrobial Agents and Chemotherapy, 2012, 56, 3406-3408.	1.4	6
68	Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution. Journal of Clinical Microbiology, 2012, 50, 2040-2046.	1.8	128
69	Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012. Journal of Clinical Microbiology, 2012, 50, 2846-2856.	1.8	391
70	Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods. Antimicrobial Agents and Chemotherapy, 2012, 56, 352-357.	1.4	82
71	Diagnosing and Reporting of Central Lineâ€“Associated Bloodstream Infections. Infection Control and Hospital Epidemiology, 2012, 33, 875-882.	1.0	36
72	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations. Antimicrobial Agents and Chemotherapy, 2012, 56, 5875-5882.	1.4	38

#	Article	IF	Citations
73	Seasonality of staphylococcal infections. Clinical Microbiology and Infection, 2012, 18, 927-933.	2.8	106
74	Evaluation of Postprescription Review and Feedback as a Method of Promoting Rational Antimicrobial Use: A Multicenter Intervention. Infection Control and Hospital Epidemiology, 2012, 33, 374-380.	1.0	82
75	Prevalence, antibiotic resistance and molecular characterisation of Staphylococcus aureus in pigs at agricultural fairs in the USA. Veterinary Record, 2012, 170, 495-495.	0.2	30
76	Bacterial Contamination of an Automated Pharmacy Robot Used for Intravenous Medication Preparation. Infection Control and Hospital Epidemiology, 2012, 33, 517-520.	1.0	4
77	Novel Hospital Curtains with Antimicrobial Properties: A Randomized, Controlled Trial. Infection Control and Hospital Epidemiology, 2012, 33, 1081-1085.	1.0	40
78	The Epidemiology of Methicillin-ResistantStaphylococcus aureuson a Burn Trauma Unit. Infection Control and Hospital Epidemiology, 2012, 33, 1118-1125.	1.0	9
79	The changing epidemiology of healthcare-associated candidemia over three decades. Diagnostic Microbiology and Infectious Disease, 2012, 73, 45-48.	0.8	278
80	Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values. Diagnostic Microbiology and Infectious Disease, 2012, 73, 365-368.	0.8	59
81	Hospital privacy curtains are frequently and rapidly contaminated with potentially pathogenic bacteria. American Journal of Infection Control, 2012, 40, 904-906.	1.1	64
82	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH AllianceÂ®) registry, 2004â€“2008. Diagnostic Microbiology and Infectious Disease, 2012, 74, 323-331.	0.8	335
83	Azole Resistance in Aspergillus fumigatus Isolates from the ARTEMIS Global Surveillance Study Is Primarily Due to the TR/L98H Mutation in the cyp51A Gene. Antimicrobial Agents and Chemotherapy, 2011, 55, 4465-4468.	1.4	211
84	Current Practice in Staphylococcus aureus Screening and Decolonization. Infection Control and Hospital Epidemiology, 2011, 32, 1042-1044.	1.0	27
85	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagnostic Microbiology and Infectious Disease, 2011, 70, 330-343.	0.8	117
86	Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States. Diagnostic Microbiology and Infectious Disease, 2011, 71, 177-180.	0.8	18
87	Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagnostic Microbiology and Infectious Disease, 2011, 71, 252-259.	0.8	56
88	Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resistance Updates, 2011, 14, 164-176.	6.5	293
89	Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins. Current Fungal Infection Reports, 2011, 5, 120-127.	0.9	4
90	Comparison of the Broth Microdilution Methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for Testing Itraconazole, Posaconazole, and Voriconazole against Aspergillus Isolates. Journal of Clinical Microbiology, 2011, 49, 1110-1112.	1.8	35

#	Article	IF	Citations
91	Methicillin-Resistant Staphylococcus aureus in Pork Production Shower Facilities. Applied and Environmental Microbiology, 2011, 77, 696-698.	1.4	17
92	Detection of Staphylococcus aureus Isolates with Heterogeneous Intermediate-Level Resistance to Vancomycin in the United States. Journal of Clinical Microbiology, 2011, 49, 4203-4207.	1.8	49
93	Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp. Journal of Clinical Microbiology, 2011, 49, 1765-1771.	1.8	28
94	Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles. Journal of Clinical Microbiology, 2011, 49, 586-590.	1.8	81
95	Clinical significance of positive cranial bone flap cultures and associated risk of surgical site infection after craniotomies or craniectomies. Journal of Neurosurgery, 2011, 114, 1746-1754.	0.9	55
96	Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program. Journal of Clinical Microbiology, 2011, 49, 1274-1279.	1.8	28
97	Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009. Antimicrobial Agents and Chemotherapy, 2011, 55, 4154-4160.	1.4	69
98	Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans , Candida glabrata , and Candida parapsilosis. Antimicrobial Agents and Chemotherapy, 2011, 55, 1543-1548.	1.4	38
99	Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution. Journal of Clinical Microbiology, 2011, 49, 630-637.	1.8	61
100	Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida. Journal of Clinical Microbiology, 2011, 49, 3800-3804.	1.8	59
101	Prevalence and Genetic Relatedness of Methicillin-Susceptible Staphylococcus aureus Isolates Detected by the Xpert MRSA Nasal Assay. Journal of Clinical Microbiology, 2011, 49, 2996-2999.	1.8	31
102	Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values. Journal of Clinical Microbiology, 2011, 49, 845-850.	1.8	60
103	Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin. Journal of Clinical Microbiology, 2011, 49, 624-629.	1.8	53
104	Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?. Current Fungal Infection Reports, 2010, 4, 168-174.	0.9	14
105	Decline in Invasive MRSA Infection. JAMA - Journal of the American Medical Association, 2010, 304, 687.	3.8	20
106	Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp. Journal of Clinical Microbiology, 2010, 48, 52-56.	1.8	143
107	In Vitro Activity of Anidulafungin and Other Agents against Esophageal Candidiasis-Associated Isolates from a Phase 3 Clinical Trial. Journal of Clinical Microbiology, 2010, 48, 2613-2614.	1.8	2
108	In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species. Antimicrobial Agents and Chemotherapy, 2010, 54, 2497-2506.	1.4	198

#	Article	IF	Citations
109	Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains. Antimicrobial Agents and Chemotherapy, 2010, 54, 2655-2659.	1.4	112
110	Wide Variability in the Use of Antimicrobial Lock Therapy and Prophylaxis among Infectious Diseases Consultants. Infection Control and Hospital Epidemiology, 2010, 31, 554-557.	1.0	10
111	Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species. Journal of Clinical Microbiology, 2010, 48, 1592-1599.	1.8	94
112	Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document). Journal of Clinical Microbiology, 2010, 48, 3251-3257.	1.8	213
113	Epidemiology of Invasive Mycoses in North America. Critical Reviews in Microbiology, 2010, 36, 1-53.	2.7	799
114	Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. International Journal of Medical Microbiology, 2010, 300, 265-270.	1.5	77
115	Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagnostic Microbiology and Infectious Disease, 2010, 67, 56-60.	0.8	24
116	Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2010, 67, 162-171.	0.8	72
117	Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resistance Updates, 2010, 13, 180-195.	6.5	259
118	Point-Counterpoint: To Screen or Not To Screen for Methicillin-Resistant Staphylococcusaureus. Journal of Clinical Microbiology, 2010, 48, 683-689.	1.8	55
119	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion. Journal of Clinical Microbiology, 2010, 48, 1366-1377.	1.8	567
120	Community-Associated Methicillin-ResistantStaphylococcus aureus, Iowa, USA. Emerging Infectious Diseases, 2009, 15, 1582-1589.	2.0	37
121	Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. Journal of Antimicrobial Chemotherapy, 2009, 63, 427-437.	1.3	194
122	Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. Journal of Clinical Microbiology, 2009, 47, 3142-3146.	1.8	129
123	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology, 2009, 47, 117-123.	1.8	205
124	Identification and Susceptibility Profile of Candida fermentati from a Worldwide Collection of Candida guilliermondii Clinical Isolates. Journal of Clinical Microbiology, 2009, 47, 242-244.	1.8	39
125	Screening of a Large Global Aspergillus fumigatus Species Complex Collection by Using a Species-Specific Microsphere-Based Luminex Assay. Journal of Clinical Microbiology, 2009, 47, 4171-4172.	1.8	18
126	In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of RareCandidaSpecies as Determined by CLSI Broth Microdilution Methods. Journal of Clinical Microbiology, 2009, 47, 3170-3177.	1.8	105

#	Article	IF	Citations
127	Variation in Susceptibility of Bloodstream Isolates ofCandida glabratato Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007. Journal of Clinical Microbiology, 2009, 47, 3185-3190.	1.8	107
128	Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature. Journal of Clinical Microbiology, 2009, 47, 1216-1217.	1.8	87
129	In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method. Journal of Clinical Microbiology, 2009, 47, 3323-3325.	1.8	94
130	A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.. Diagnostic Microbiology and Infectious Disease, 2009, 63, 233-236.	0.8	22
131	Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagnostic Microbiology and Infectious Disease, 2009, 64, 152-157.	0.8	39
132	Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2009, 65, 27-34.	0.8	23
133	Adverse outcomes associated with contact precautions: A review of the literature. American Journal of Infection Control, 2009, 37, 85-93.	1.1	283
134	Activity of MGCD290, a Hos2 Histone Deacetylase Inhibitor, in Combination with Azole Antifungals against Opportunistic Fungal Pathogens. Journal of Clinical Microbiology, 2009, 47, 3797-3804.	1.8	117
135	Staphylococcus aureus Nasal Colonization and Colonization or Infection at Other Body Sites in Patients on a Burn Trauma Unit. Infection Control and Hospital Epidemiology, 2009, 30, 721-726.	1.0	18
136	Methicillin-Resistant Staphylococcus aureus (MRSA) Strain ST398 Is Present in Midwestern U.S. Swine and Swine Workers. PLoS ONE, 2009, 4, e4258.	1.1	383
137	Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis. Journal of Clinical Microbiology, 2008, 46, 2659-2664.	1.8	176
138	Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagnostic Microbiology and Infectious Disease, 2008, 60, 273-277.	0.8	71
139	Development of a Prediction Rule for Methicillin-ResistantStaphylococcus aureusand Vancomycin-ResistantEnterococcusCarriage in a Veterans Affairs Medical Center Population. Infection Control and Hospital Epidemiology, 2008, 29, 969-971.	1.0	19
140	Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method. Antimicrobial Agents and Chemotherapy, 2008, 52, 4175-4177.	1.4	40
141	Molecular Phylogenetic Analysis of a Geographically and Temporally Matched Set ofCandida albicansIsolates from Humans and Nonmigratory Wildlife in Central Illinois. Eukaryotic Cell, 2008, 7, 1475-1486.	3.4	47
142	Lodderomyces elongisporus Masquerading as Candida parapsilosis as a Cause of Bloodstream Infections. Journal of Clinical Microbiology, 2008, 46, 374-376.	1.8	89
143	Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program. Journal of Clinical Microbiology, 2008, 46, 551-559.	1.8	60
144	Geographic and Temporal Trends in Isolation and Antifungal Susceptibility of Candida parapsilosis : a Global Assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 842-849.	1.8	96

#	Article	IF	Citations
145	Candida krusei , a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology, 2008, 46, 515-521.	1.8	195
146	Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin. Journal of Clinical Microbiology, 2008, 46, 2155-2159.	1.8	59
147	Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program. Journal of Clinical Microbiology, 2008, 46, 3585-3590.	1.8	46
148	Preventing MRSA Infections. JAMA - Journal of the American Medical Association, 2008, 299, 1190.	3.8	32
149	In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species. Journal of Clinical Microbiology, 2008, 46, 2568-2572.	1.8	121
150	In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2008, 52, 3497-3503.	1.4	126
151	In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrobial Agents and Chemotherapy, 2008, 52, 539-550.	1.4	133
152	In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. Journal of Clinical Microbiology, 2008, 46, 150-156.	1.8	363
153	Strainâ€Relatedness of Methicillinâ€ResistantStaphylococcus aureusIsolates Recovered from Patients with Repeated Infection. Clinical Infectious Diseases, 2008, 46, 1241-1247.	2.9	51
154	Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. Journal of Clinical Microbiology, 2008, 46, 2620-2629.	1.8	231
155	Nonmenstrual Toxic Shock Syndrome Due to Methicillin-Resistant Staphylococcus aureus. Obstetrics and Gynecology, 2008, 112, 933-938.	1.2	9
156	Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. Journal of Clinical Microbiology, 2007, 45, 796-802.	1.8	68
157	Evaluation of Disk Diffusion and Etest Compared to Broth Microdilution for Antifungal Susceptibility Testing of Posaconazole against Clinical Isolates of Filamentous Fungi. Journal of Clinical Microbiology, 2007, 45, 1322-1324.	1.8	28
158	Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. Journal of Clinical Microbiology, 2007, 45, 1735-1745.	1.8	269
159	Antimicrobial Resistance among Gram-Negative Bacilli Causing Infections in Intensive Care Unit Patients in the United States between 1993 and 2004. Journal of Clinical Microbiology, 2007, 45, 3352-3359.	1.8	310
160	Improving Methicillinâ€ResistantStaphylococcus aureusSurveillance and Reporting in Intensive Care Units. Journal of Infectious Diseases, 2007, 195, 330-338.	1.9	100
161	Multicenter Comparison of the VITEK 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Amphotericin B, Flucytosine, and Voriconazole against Candida spp. Journal of Clinical Microbiology, 2007, 45, 3522-3528.	1.8	121
162	Evaluation of Etest and Disk Diffusion Methods Compared with Broth Microdilution Antifungal Susceptibility Testing of Clinical Isolates of Candida spp. against Posaconazole. Journal of Clinical Microbiology, 2007, 45, 1974-1977.	1.8	28

#	Article	IF	Citations
163	Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods. Journal of Clinical Microbiology, 2007, 45, 70-75.	1.8	80
164	Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates. Fungal Genetics and Biology, 2007, 44, 1298-1309.	0.9	42
165	Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clinical Microbiology Reviews, 2007, 20, 133-163.	5.7	3,459
166	An Outbreak of Severe Clostridium difficileâ€"Associated Disease Possibly Related to Inappropriate Antimicrobial Therapy for Community-Acquired Pneumonia. Infection Control and Hospital Epidemiology, 2007, 28, 212-214.	1.0	73
167	Look before You Leap: Active Surveillance for Multidrug-Resistant Organisms. Clinical Infectious Diseases, 2007, 44, 1101-1107.	2.9	108
168	Healthcare-associated Fungal Infections: Beyond Candida and Aspergillus. Southern Medical Journal, 2007, 100, 130-131.	0.3	1
169	Influenza Vaccination Rates, Feedback, and the Hawthorne Effect. Infection Control and Hospital Epidemiology, 2006, 27, 98-99.	1.0	7
170	Risk Factors for Groin Wound Infection After Femoral Artery Catheterization A Case-Control Study. Infection Control and Hospital Epidemiology, 2006, 27, 34-37.	1.0	4
171	Epidemiology of Methicillin-ResistantStaphylococcus aureusand Vancomycin-ResistantEnterococcusin a Rural State. Infection Control and Hospital Epidemiology, 2006, 27, 252-256.	1.0	19
172	A Multicenter Intervention to Prevent Catheter-Associated Bloodstream Infections. Infection Control and Hospital Epidemiology, 2006, 27, 662-669.	1.0	123
173	Descriptive Epidemiology and Case-Control Study of Patients Colonized With Vancomycin-Resistant Enterococcus and Methicillin-ResistantStaphylococcus aureus. Infection Control and Hospital Epidemiology, 2006, 27, 913-919.	1.0	10
174	Antimicrobial Use Control Measures to Prevent and Control Antimicrobial Resistance in US Hospitals. Infection Control and Hospital Epidemiology, 2006, 27, 1088-1095.	1.0	48
175	Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagnostic Microbiology and Infectious Disease, 2006, 55, 209-212.	0.8	66
176	A case of recurrent episodes of Candida parapsilosis fungemia. Mycopathologia, 2006, 162, 295-298.	1.3	6
177	Candida rugosa , an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 3578-3582.	1.8	88
178	Global Surveillance of In Vitro Activity of Micafungin against Candida : a Comparison with Caspofungin by CLSI-Recommended Methods. Journal of Clinical Microbiology, 2006, 44, 3533-3538.	1.8	84
179	Candida guilliermondii , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program. Journal of Clinical Microbiology, 2006, 44, 3551-3556.	1.8	160
180	Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp.. Journal of Clinical Microbiology, 2006, 44, 324-326.	1.8	91

#	Article	IF	Citations
181	Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clinical Microbiology Reviews, 2006, 19, 435-447.	5.7	255
182	In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance. Journal of Clinical Microbiology, 2006, 44, 760-763.	1.8	173
183	Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints. Journal of Clinical Microbiology, 2006, 44, 819-826.	1.8	225
184	In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans , and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. Journal of Clinical Microbiology, 2005, 43, 3807-3810.	1.8	71
185	Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. Journal of Clinical Microbiology, 2005, 43, 5208-5213.	1.8	62
186	Unusual Fungal and Pseudofungal Infections of Humans. Journal of Clinical Microbiology, 2005, 43, 1495-1504.	1.8	70
187	DiskDiffusion Testing Using Candida sp. Colonies Taken Directlyfrom CHROMagar Candida Medium May Decrease Time Required To ObtainResults. Journal of Clinical Microbiology, 2005, 43, 3497-3499.	1.8	8
188	Activities of Available and Investigational Antifungal Agents against Rhodotorula Species. Journal of Clinical Microbiology, 2005, 43, 476-478.	1.8	109
189	Results from the ARTEMIS DISK Global AntifungalSurveillance Study: a 6.5-Year Analysis of Susceptibilitiesof Candida and Other Yeast Species to Fluconazole andVoriconazole by Standardized Disk Diffusion Testing. Journal of Clinical Microbiology, 2005, 43, 5848-5859.	1.8	193
190	Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4795-4797.	1.4	53
191	Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004). Journal of Clinical Microbiology, 2005, 43, 2163-2167.	1.8	183
192	In Vitro Activities of Anidulafungin against More than 2,500 Clinical Isolates of Candida spp., Including 315 Isolates Resistant to Fluconazole. Journal of Clinical Microbiology, 2005, 43, 5425-5427.	1.8	155
193	Implementation of Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in U.S. Hospitals. Infection Control and Hospital Epidemiology, 2005, 26, 21-30.	1.0	19
194	Variation in the Use of Procedures to Monitor Antimicrobial Resistance in U.S. Hospitals. Infection Control and Hospital Epidemiology, 2005, 26, 31-38.	1.0	8
195	Importance of Control Group Selection for Evaluating Antimicrobial Use as a Risk Factor for Methicillin-ResistantStaphylococcus AureusBacteremia. Infection Control and Hospital Epidemiology, 2005, 26, 634-637.	1.0	13
196	Varying Rates of Clostridium Difficile-Associated Diarrhea at Prevention Epicenter Hospitals. Infection Control and Hospital Epidemiology, 2005, 26, 676-679.	1.0	43
197	Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases. Journal of Clinical Microbiology, 2005, 43, 2155-2162.	1.8	362
198	Determining the Clinical Significance of Coagulase-Negative Staphylococci Isolated From Blood Cultures. Infection Control and Hospital Epidemiology, 2005, 26, 559-566.	1.0	148

#	Article	IF	Citations
199	Enhanced Identification of Postoperative Infections among Inpatients. Emerging Infectious Diseases, 2004, 10, 1924-1930.	2.0	113
200	Rapid Detection of Antimicrobial-Resistant Organism Carriage: an Unmet Clinical Need. Journal of Clinical Microbiology, 2004, 42, 2879-2883.	1.8	63
201	Comparison of Results of Fluconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. Journal of Clinical Microbiology, 2004, 42, 3607-3612.	1.8	59
202	Accuracy and Appropriateness of Antimicrobial Susceptibility Test Reporting for Bacteria Isolated from Blood Cultures. Journal of Clinical Microbiology, 2004, 42, 2258-2260.	1.8	19
203	Evaluation of the Etest Method Using Mueller-Hinton Agar with Glucose and Methylene Blue for Determining Amphotericin B MICs for 4,936 Clinical Isolates of Candida Species. Journal of Clinical Microbiology, 2004, 42, 4977-4979.	1.8	49
204	Cross-Resistance between Fluconazole and Ravuconazole and the Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Ravuconazole among 12,796 Clinical Isolates of Candida spp. Journal of Clinical Microbiology, 2004, 42, 3137-3141.	1.8	61
205	Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002. Journal of Clinical Microbiology, 2004, 42, 3142-3146.	1.8	163
206	Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole. Journal of Clinical Microbiology, 2004, 42, 380-383.	1.8	27
207	Stability of Mueller-Hinton Agar Supplemented with Glucose and Methylene Blue for Disk Diffusion Testing of Fluconazole and Voriconazole. Journal of Clinical Microbiology, 2004, 42, 1288-1289.	1.8	21
208	Further Standardization of Broth Microdilution Methodology for In Vitro Susceptibility Testing of Caspofungin against Candida Species by Use of an International Collection of More than 3,000 Clinical Isolates. Journal of Clinical Microbiology, 2004, 42, 3117-3119.	1.8	85
209	Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals. Clinical Infectious Diseases, 2004, 38, 78-85.	2.9	232
210	Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people*. HIV Medicine, 2004, 5, 144-150.	1.0	45
211	Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis. Clinical Infectious Diseases, 2004, 39, 584-587.	2.9	278
212	Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus. Journal of Clinical Microbiology, 2004, 42, 4419-4431.	1.8	623
213	Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure. Infection Control and Hospital Epidemiology, 2004, 25, 624-626.	1.0	51
214	In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagnostic Microbiology and Infectious Disease, 2004, 48, 201-205.	0.8	223
215	In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagnostic Microbiology and Infectious Disease, 2004, 48, 101-105.	0.8	81
216	Are United States hospitals following national guidelines for the analysis and presentation of cumulative antimicrobial susceptibility data?. Diagnostic Microbiology and Infectious Disease, 2004, 49, 141-145.	0.8	34

#	Article	IF	Citations
217	Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans. Diagnostic Microbiology and Infectious Disease, 2004, 50, 113-117.	0.8	10
218	Prenatal testing for infectious disease. Clinics in Laboratory Medicine, 2003, 23, 295-315.	0.7	4
219	Prevalence of the Use of Central Venous Access Devices Within and Outside of the Intensive Care Unit: Results of a Survey Among Hospitals in the Prevention Epicenter Program of the Centers for Disease Control and Prevention. Infection Control and Hospital Epidemiology, 2003, 24, 942-945.	1.0	129
220	Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida. Journal of Clinical Microbiology, 2003, 41, 5729-5731.	1.8	106
221	In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 1068-1071.	1.4	150
222	In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference M38-A microdilution methods for determining posaconazole MICs. Diagnostic Microbiology and Infectious Disease, 2003, 45, 241-244.	0.8	43
223	Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi. Journal of Clinical Microbiology, 2003, 41, 3623-3626.	1.8	352
224	Epidemiology and Outcome of Nosocomial and Community-Onset Bloodstream Infection. Journal of Clinical Microbiology, 2003, 41, 3655-3660.	1.8	261
225	Attributable Mortality of Nosocomial Candidemia, Revisited. Clinical Infectious Diseases, 2003, 37, 1172-1177.	2.9	1,046
226	In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from Blood. Journal of Clinical Microbiology, 2003, 41, 78-83.	1.8	155
227	Evaluation of Etest Method for Determining Fluconazole and Voriconazole MICs for 279 Clinical Isolates of Candida Species Infrequently Isolated from Blood. Journal of Clinical Microbiology, 2003, 41, 1087-1090.	1.8	45
228	Molecular Epidemiology of Macrolide Resistance in Neonatal Bloodstream Isolates of Group B Streptococci. Journal of Clinical Microbiology, 2003, 41, 2659-2661.	1.8	42
229	Evaluation of the Etest and Disk Diffusion Methods for Determining Susceptibilities of 235 Bloodstream Isolates of Candida glabrata to Fluconazole and Voriconazole. Journal of Clinical Microbiology, 2003, 41, 1875-1880.	1.8	50
230	Fluoroquinolone Resistance inStreptococcus pyogenes. Clinical Infectious Diseases, 2003, 36, 380-383.	2.9	34
231	Detection and Treatment of Bloodstream Infection: Laboratory Reporting and Antimicrobial Management. Journal of Clinical Microbiology, 2003, 41, 495-497.	1.8	157
232	In Vitro Susceptibility Testing of Aspergillus spp.: Comparison of Etest and Reference Microdilution Methods for Determining Voriconazole and Itraconazole MICs. Journal of Clinical Microbiology, 2003, 41, 1126-1129.	1.8	80
233	Effects of Rapid Detection of Bloodstream Infections on Length of Hospitalization and Hospital Charges. Journal of Clinical Microbiology, 2003, 41, 3119-3125.	1.8	171
234	Use of Active Surveillance Cultures to Control Vancomycin-Resistant Enterococcus. Clinical Infectious Diseases, 2003, 37, 1400-1402.	2.9	3

#	Article	IF	Citations
235	Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001. Journal of Clinical Microbiology, 2003, 41, 1440-1446.	1.8	155
236	Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location. Journal of Clinical Microbiology, 2003, 41, 2176-2179.	1.8	90
237	Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of Cryptococcus neoformans. Journal of Clinical Microbiology, 2003, 41, 97-99.	1.8	35
238	Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility. Journal of Clinical Microbiology, 2002, 40, 3551-3557.	1.8	236
239	In Vitro Activities of 5-Fluorocytosine against 8,803 Clinical Isolates of Candida spp.: Global Assessment of Primary Resistance Using National Committee for Clinical Laboratory Standards Susceptibility Testing Methods. Antimicrobial Agents and Chemotherapy, 2002, 46, 3518-3521.	1.4	116
240	Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study. Journal of Clinical Microbiology, 2002, 40, 1298-1302.	1.8	329
241	Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. Journal of Clinical Microbiology, 2002, 40, 852-856.	1.8	290
242	Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole. Journal of Clinical Microbiology, 2002, 40, 1694-1697.	1.8	14
243	Minimizing the Workup of Blood Culture Contaminants: Implementation and Evaluation of a Laboratory-Based Algorithm. Journal of Clinical Microbiology, 2002, 40, 2437-2444.	1.8	126
244	Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America. International Journal of Antimicrobial Agents, 2002, 20, 412-418.	1.1	95
245	Effect of Coinfection with GB Virus C on Survival among Patients with HIV Infection. New England Journal of Medicine, 2001, 345, 707-714.	13.9	353
246	Surveillance of antibiotic resistance in European ICUs. Journal of Hospital Infection, 2001, 48, 161-176.	1.4	108
247	Oxazolidinone antibiotics. Lancet, The, 2001, 358, 1975-1982.	6.3	356
248	Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clinical Microbiology and Infection, 2001, 7, 152-157.	2.8	55
249	Comparison of the Vitek Gram-Positive Susceptibility 106 Card, the MRSA-Screen Latex Agglutination Test, and mecA Analysis for Detecting Oxacillin Resistance in a Geographically Diverse Collection of Clinical Isolates of Coagulase-Negative Staphylococci. Journal of Clinical Microbiology, 2001, 39, 3633-3636.	1.8	38
250	International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. Journal of Clinical Microbiology, 2001, 39, 3254-3259.	1.8	475
251	Evaluation of Current Methods for Detection of Staphylococci with Reduced Susceptibility to Glycopeptides. Journal of Clinical Microbiology, 2001, 39, 2439-2444.	1.8	290
252	Comparison of the Vitek Gram-Positive Susceptibility 106 Card and the MRSA-Screen Latex Agglutination Test for Determining Oxacillin Resistance in Clinical Bloodstream Isolates of Staphylococcus aureus. Journal of Clinical Microbiology, 2001, 39, 53-56.	1.8	50

#	Article	IF	Citations
253	Group B streptococci causing neonatal bloodstream infection: Antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. American Journal of Obstetrics and Gynecology, 2000, 183, 859-862.	0.7	103
254	Genetic Relatedness of Multidrug-Resistant, Methicillin (Oxacillin)-ResistantStaphylococcus aureusBloodstream Isolates from SENTRY Antimicrobial Resistance Surveillance Centers Worldwide, 1998. Microbial Drug Resistance, 2000, 6, 213-221.	0.9	55
255	Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. International Journal of Antimicrobial Agents, 2000, 13, 257-271.	1.1	114
256	Oxazolidinones. Drugs, 2000, 59, 7-16.	4.9	198
257	Antimicrobial-Drug Use and Changes in Resistance in Streptococcus pneumoniae. Emerging Infectious Diseases, 2000, 6, 552-556.	2.0	80
258	Clinical impact of changing to an automated blood-culture system at a small community hospital. Clinical Microbiology and Infection, 1999, 5, 590-593.	2.8	1
259	Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers. Diagnostic Microbiology and Infectious Disease, 1999, 34, 37-43.	0.8	37
260	Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagnostic Microbiology and Infectious Disease, 1999, 35, 81-88.	0.8	22
261	An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagnostic Microbiology and Infectious Disease, 1997, 29, 147-153.	0.8	90
262	Blood and body fluid exposures during clinical training. Journal of General Internal Medicine, 1996, 11, 109-111.	1.3	22
263	Universal Precautions Training of Preclinical Students: Impact on Knowledge, Attitudes, and Compliance. Preventive Medicine, 1995, 24, 580-585.	1.6	30
264	Employee Health and Infection Control. Infection Control and Hospital Epidemiology, 1995, 16, 292-301.	1.0	15